Welcome to our dedicated page for Enochian Biosciences news (Ticker: ENOB), a resource for investors and traders seeking the latest updates and insights on Enochian Biosciences stock.
Enochian Biosciences, Inc. (ENOB) is a clinical-stage biopharmaceutical company developing innovative immunotherapies targeting HIV/AIDS and cancer. This dedicated news hub provides investors and stakeholders with timely updates on therapeutic advancements, regulatory milestones, and corporate developments.
Access authoritative information about ENOB's research pipeline including ENO-1001 (pre-IND HIV cure candidate) and ENO-3001 (colon cancer relapse prevention). The page consolidates official announcements regarding clinical trial progress, SEC filings, partnership opportunities, and strategic business decisions.
Key updates cover three critical areas: 1) Clinical development stages across therapeutic candidates 2) Regulatory interactions and compliance updates 3) Financial performance and stockholder communications. All content is sourced from verified corporate disclosures to ensure reliability.
Bookmark this page for streamlined access to Enochian Biosciences' latest news. For complete investment context, always cross-reference updates with official SEC filings and company-issued documentation.
Enochian BioSciences (NASDAQ: ENOB) announced promising findings presented by Dr. Serhat Gumrukçu at the International Liver Conference, showing that a novel cellular therapy reduced Hepatitis B Virus (HBV) to undetectable levels by the 8th day without toxicities. The company holds an exclusive license for this technology, Hijack RNA, which also shows potential against influenza and coronaviruses, including COVID-19. These advancements could impact global health, particularly for the 350 million HBV patients worldwide.
Enochian BioSciences has acquired an exclusive license for a novel technology aimed at treating and preventing all variants of coronavirus, including COVID-19, and influenza. The company plans to submit a request for a Pre-Investigator New Drug meeting with the FDA shortly. This innovative technology employs nanoparticles to induce infected cells to self-destruct, potentially allowing a single inhalation to provide both treatment and long-term protection against infections. The technology targets a common region in SARS-CoV-2 variants, offering hope amid concerns over vaccine effectiveness.
Enochian BioSciences (NASDAQ: ENOB) is advancing a promising HIV treatment closer to FDA approval. The Seraph Research Institute (SRI), led by Dr. Serhat Gumrukcu, has secured a Pre-Investigational New Drug (Pre-IND) meeting with the FDA to discuss its immune-based cell therapy. Initial results from a patient's treatment indicate a sustained undetectable viral load, potentially allowing for a functional cure. This milestone may pave the way for alternative HIV treatments beyond daily antiviral medications.
Enochian BioSciences, Inc. has announced a definitive securities purchase agreement to issue 3,866,667 shares at $7.50 each, raising approximately $29 million before fees. The registered direct offering, expected to close around June 16, 2021, aims to fund working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent. This offering is being conducted under a shelf registration statement filed with the SEC. The company focuses on gene-modified therapies targeting infectious diseases and cancer.
Enochian BioSciences has announced that the FDA accepted its Pre-IND request for a potential functional cure for HIV. This follows the promising results from a 54-year-old patient who achieved viral control for 255 days using Natural Killer and Gamma Delta T-cells without antiviral drugs. The findings will be further evaluated in a larger population to explore treatment possibilities for those with suppressed HIV. Experts in the field express optimism about the potential to alleviate the burden of daily antiviral medications.
Enochian BioSciences announced promising preliminary data on a novel cell therapy for HIV, presented by Dr. Serhat Gumrukçu at the ASGCT Annual Meeting. A 54-year-old patient, after 35 years of HIV infection, showed significant declines in viral load post-treatment. The therapy, involving NK and gamma delta T-cells, resulted in undetectable HIV levels after 100 days and sustained this status for 255 days without antiviral medication. The company is pursuing FDA approval to expand testing, which may lead to a functional cure for HIV and address unmet medical needs in treatment options.
LOS ANGELES, May 12, 2021 /PRNewswire/ -- Enobia (NASDAQ: ENOB) unveiled promising results of a novel HIV cell therapy presented by Dr. Serhat Gumrukçu at the ASGCT meeting. A 54-year-old HIV patient showed a decline in viral load to below detectable levels (<20 copies/ml) after receiving immune-based cell therapy over 100 days. Dr. Phillip Musikanth discussed the innovative approach utilizing natural killer and gamma delta T-cells. This study marks a significant advancement in HIV treatment, with ongoing regulatory application for clinical trials.
Enochian BioSciences (NASDAQ: ENOB) announced promising preliminary data regarding a new cell therapy aimed at controlling HIV in humans. Presented by Dr. Serhat Gumrukçu at the ASGCT Annual Meeting, the therapy involved a single patient who had been HIV-positive since 1986. Following treatment with natural killer and gamma delta T-cells, the patient's HIV levels dropped below detectable limits for over 255 days, even without antiviral medication. This approach could lead to a functional cure for HIV, with Enochian pursuing further research through the FDA.
Enochian BioSciences (NASDAQ: ENOB) and Seraph Research Institute announced a significant clinical outcome: a 36-year-old patient with recurrent glioblastoma achieved complete remission for 15 months. This case highlights a rare response to this aggressive brain cancer, documented in the American Journal of Case Reports. The patient was treated with genetically modified immune cells loaded with a cytomegalovirus component often found in glioblastomas. Enochian is advancing this technology for potential applications in pancreatic cancer and other solid tumors.
Enochian BioSciences will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Executive Vice Chair Dr. Mark Dybul will discuss advancements in the company's HIV, Hepatitis B, and Oncology platforms. The presentation will be accessible on-demand starting at 7 am Eastern. On March 10, Dr. Dybul and CFO Luisa Puche will engage in live one-on-one meetings with registered investors. For more details, attendees can visit the conference website.
